Newsfeeds - Spark Newswire

4 minute read

FDA
News

ANI Pharmaceuticals Announces FDA Approval Of Purified Cortrophin Gel For Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis And Nephrotic Syndrome

November 1, 6:31 AM

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified

ANIP

7 minute read

Earnings Scheduled For November 1, 2021

By Benzinga Insights

November 1, 4:01 AM

Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter.

ADC

4 minute read

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs

By Shanthi Rexaline

October 29, 8:00 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

October 24, 11:45 AM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV

7 minute read

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

By Shanthi Rexaline

October 1, 2:15 PM

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.

ANIP

1 minute read

ANI Pharma Reports Launch Of Nebivolol Tablets

By Benzinga Newsdesk

September 17, 6:51 AM

-- Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion -- -- Simultaneous launch from two manufacturing sites -- BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI

ANIP

2 minute read

Earnings

Looking Into ANI Pharmaceuticals’s Return On Capital Employed

By Benzinga Insights

September 9, 1:15 PM

Benzinga Pro data, ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 sales of $48.62 million. Earnings fell to a loss of $15.55 million, resulting in a 610.77% decrease from last quarter.

ANIP

1 minute read

ANI Pharma’s Purified Cortrophin Gel Application Under FDA Review

By Vandana Singh

August 31, 9:57 AM

The FDA has accepted ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) supplemental marketing application for Purified Cortrophin Gel. The application seeks approval for multiple…

ANIP

1 minute read

Recap: ANI Pharmaceuticals Q2 Earnings

By Benzinga Insights

August 6, 7:52 AM

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 2.90% year over year to $0.67, which missed the estimate of $0.68.

ANIP

6 minute read

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO

By Shanthi Rexaline

August 6, 7:42 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)

ACAD